ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 6.3% in November

ADMA Biologics, Inc. (NASDAQ:ADMA) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 14,240,000 shares, a decrease of 6.3% from the October 31st total of 15,200,000 shares. Based on an average trading volume of 5,080,000 shares, the short-interest ratio is currently 2.8 days.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently modified their holdings of the stock. Quest Partners LLC purchased a new position in ADMA Biologics during the second quarter valued at $29,000. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics in the third quarter worth about $30,000. Larson Financial Group LLC bought a new position in ADMA Biologics during the third quarter valued at approximately $31,000. National Bank of Canada FI purchased a new position in ADMA Biologics during the 3rd quarter valued at approximately $35,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in ADMA Biologics in the 3rd quarter worth approximately $62,000. Institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

ADMA has been the topic of several recent analyst reports. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $20.11 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock’s fifty day moving average is $19.08 and its 200 day moving average is $15.40. The stock has a market cap of $4.75 billion, a P/E ratio of 71.82 and a beta of 0.64. ADMA Biologics has a one year low of $3.60 and a one year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the prior year, the company posted $0.01 earnings per share. Sell-side analysts anticipate that ADMA Biologics will post 0.52 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.